Threshold Pharmaceuticals

Threshold earns $20 million milestone payment from Merck

Wednesday, April 11, 2012 11:50 AM

Threshold Pharmaceuticals, a biotech based in South San Francisco, has earned a $20 million milestone payment from Merck for achieving a statistically significant progression free survival benefit in its 214-patient randomized controlled phase II clinical trial (404 trial).

More... »


Burrill wraps up life sciences industry for Q1 2012

Wednesday, April 4, 2012 03:00 PM

Burrill & Company, a diversified global financial services firm focused on the life sciences industry, has identified more than $2.6 billion in expected funding through nine translational research and early-stage initiatives announced since the end of February.

More... »


Positive phase IIb results in Threshold pancreatic cancer trial

Friday, February 24, 2012 11:13 AM

Threshold Pharmaceuticals’ TH-302 combination phase IIb study for pancreatic cancer has reached its primary endpoint with a 63% improvement in progression free survival and a safety profile consistent with previous studies.

More... »

Threshold, Merck to collaborate

Monday, February 6, 2012 01:51 PM

Threshold Pharmaceuticals has signed a global agreement with Germany-based Merck to co-develop and commercialize TH-302, Threshold's small molecule hypoxia-targeted drug.

More... »


CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks worldwide toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs